Detail of "63983-53-9"

Reference

Differential synthesis and metabolism of prostaglandins and thromboxanes released from normal and sensitized guinea pig lungs

Differential synthesis and metabolism of prostaglandins and thromboxanes released from normal and sensitized guinea pig lungs. Boot, J. R.; Cockerill, A. F.; Dawson, W.; Mallen, D. N. B.; Osborne, D. J. (Lilly Res. Cent. Ltd., Windlesham, Engl.). J. Physiol. (London), 269(1), 66P-67P (English) 1977. CODEN: JPHYA7. DOCUMENT TYPE: Journal CA Section: 3 (Biochemical Interactions) Section cross-reference(s): 15 After ovalbumin sensitization (100 mg, s.c. or i.p.) followed by 2 or 5 weekly challenges with 1% ovalbumin beginning 3 weeks later, release of 6-oxo-PGF1.alpha. [58962-34-8], 6:15 dioxo- dihydro-PGF1.alpha. [63983-53-9], thromboxane B2 [54397-85-2], and 15-oxo- dihydrothromboxane B2 [62107-18-0] by arachidonic acid-perfused lungs of the guinea pig was 11, 1, 10, and 74% resp. of prostaglandinlike compds. Lungs of nonsensitized animals released 40, 12, 32, and 6% resp. and those of sensitized, unchallenged animals 18, 4, 38, and 27% resp. of these substances. The total of prostaglandinlike products isolated from each group was quant. similar (1.5 .mu.g/guinea pig).

Measurement of human venous plasma prostacyclin and metabolites by radioimmunoassay: a reappraisal

Measurement of human venous plasma prostacyclin and metabolites by radioimmunoassay: a reappraisal. Forder, Robert A.; Carey, Frank (Pharm. Div., ICI Pharm., Macclesfield/Cheshire SK10 4TG, UK). Prostaglandins, Leukotrienes Med., 12(3), 323-46 (English) 1983. CODEN: PLMEDD. ISSN: 0262-1746. DOCUMENT TYPE: Journal CA Section: 2 (Mammalian Hormones) Two RIAs, the 1st specific for 6-oxo-PGF1a [58962-34-8] and the 2nd for 6-oxo-PGF1a, 13,14-dihydro-6-oxo-PGF1a [71310-60-6], 13,14-dihydro-6,15-dioxo-PGF1a [63983-53-9], and 6-oxo-PGE1 [67786-53-2] were described. These RIAs were used to measure levels of immunoreactive 6-oxo-PGF1a and alleged metabolites of prostacyclin in human venous plasma. Procedures for the direct measurement and extn. of plasma 6-oxo-PGF1a were described and the limitations to which RIA of plasma 6-oxo-PGF1a is exposed were discussed. Direct measurement of plasma immunoreactive 6-oxo-PGF1a gave maximal levels of 6.1 pg/mL and 4 pg/mL in the 1st and 2nd RIAs, resp. The latter value reflected combined levels of <2 pg/mL of 6-oxo-PGF1a and cross-reacting metabolites in venous blood. Extn. of human plasma gave 88.7% recovery of [3H]6-oxo-PGF1a and 80-86% recovery of exogenous 6-oxo-PGF1a as immunoreactive 6-oxo-PGF1a. Basal plasma levels of extractable immunoreactive 6-oxo-PGF1a were <2.5 pg/mL. Prostacyclin [35121-78-9] incubated in vitro with blood was recovered in plasma as immunoreactive 6-oxo-PGF1a and confirmed that conversion to metabolites that cross-reacted with the 2nd antibody, in particular 6-oxo-PGF1, did not occur under exptl. 35121-78-9 and 58962-34-8 which are cas registry numbers of chemicals are mentioned. conditions. Extn. of [3H]6-oxo-PGF1a from acidified plasma with MeOH resulted in formation of a prostanoid that had properties consistent with the methylated hemiketal isomer of 6-oxo-PGF1a. Under RIA conditions this prostanoid was less immunogenic than native [3H]6-oxo-PGF1a and [3H]6-oxo-PGF1a extd. from plasma using Me formate. The low levels of plasma 6-oxo-PGF1a reported questions the validity of clin. studies that previously described altered levels of plasma 6-oxo-PGF1a in pathophysiol. conditions. .